Introduction {#sec1-1}
============

Type 2 diabetes mellitus (T2DM) is one of the major health-related global health problems \[[@ref1]\]. Genetic alterations played an important role in determining why some diabetic patients develop these complications while others do not \[[@ref2]\]. Several evidence showed the importance of inflammation in the pathogenesis of diabetic complications, especially enhancement of atherosclerosis and complications \[[@ref3]\]. According to the International Diabetes Federation revealed that currently, around 415 million people with diabetes all over the world are likely to increase to 642 million by 2040 \[[@ref4]\]. T2D accounts for high morbidity and mortality due to complications like renal failure, amputations, cardiovascular disease, and cerebrovascular events \[[@ref5]\]. In 2015 there were approximately 5.0 million deaths by diabetes worldwide \[[@ref4]\]. C-reactive protein (CRP) is an inflammatory marker associated with T2DM, obesity, insulin resistance, and cardiovascular disease \[[@ref6]\].

Furthermore, according to recent data, CRP is not an acute phase protein only, but it is a mediator of atherogenesis, serving as a marker for cardiovascular disease (CVD) \[[@ref7]\]. CRP levels display extensive interindividual variability. Although plasma C reactive protein levels are influenced by sociodemographic, behavioural, and lifestyle factors and obesity and type 2 diabetes, twin and family studies have estimated that genetic factors could contribute up to 35--50% of the variation of CRP \[[@ref8]\] \[[@ref9]\]. Several population-based association studies have shown that common genetic variants at the *CRP* locus are significantly associated with plasma CRP levels \[[@ref10]\]. CRP gene polymorphisms of were found to be in mild to moderate association with the basal CRP levels in healthy men and women \[[@ref11]\].

Thus, the current study aimed to evaluate the role of *CRP* (+1059G/C) polymorphism in type 2 diabetic patients.

Material and Methods {#sec1-2}
====================

The present case-control study enrolled a total of 200 individuals. There were 100 newly diagnosed type 2 diabetes and 100 healthy controls collected. This study was approved by the institutional ethical committee, Jamia Millia University. Written informed consent was obtained from all individual participants included in the study.

All the clinical parameter such as fasting glucose and postprandial glucose were taken care as per standard criteria. Total 3 ml of blood sample were withdrawn, 1 collected in EDTA vials and 2 ml in plain vials from all the study subjects included in the study.

DNA isolation was done by a phenol-chloroform method from blood samples collected in EDTA vials from cases as well as controls. Genomic DNA was analysed on 1% agarose gel to confirm and observed under UV transilluminator.

Isolated DNA was then amplified to determine the genotypes of CRP by allele-specific primers forward: 5′ CATTTGTACAAGCTGGGAGT 3′, 2. Allele C specific reverse: 5′ ATGGTGTTAATCTCATCTGGTGGG 3′, Allele G specific reverse: 5'′TGGTGTTAATCTCATCTGGTGGC 3′ using thermocycler. PCR was performed in 25 μl reaction volume containing 3 μl of 100 ng template DNA, 0.25 μl of 25 pmol each primer, 2.5 μl of 10 mM dNTPs, 1.5 μl of 20mM MgCl2, 0.3 μl of 5 U/μl Taq polymerase with 2.5 μl of 10X Taq Buffer (Fermantas) and 14.7 μl of nuclease-free ddH2O. The PCR was performed with initial denaturation at 94°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 40 seconds, annealing at 58°C for 40 seconds, extension at 72°C for 40 seconds and the final extension was at 72°C for 10 minutes. The amplified product of 237 bp was visualised under UV transilluminator.

Genotype frequencies between the cases and controls were evaluated using the Chi-square test and values ≤ 5 were analysed by Fisher exact test. Allele frequency was calculated by the Hardy--Weinberg Equilibrium (HWE) equation. The associations between *CRP* genotypes and risk of T2D were estimated by computing the odds ratios (ORs) with 95% confidence intervals (CIs). The parametric and nonparametric test was used to analyse the quantitative data, p-value less than 0.05 considered to be statistically significant.

Results {#sec1-3}
=======

Demographic characteristic of study subjects investigated in the present study has been summarised in [Table 1](#T1){ref-type="table"}.

###### 

Distribution of selected characteristics among T2D patients and healthy controls

  Variables                      T2D patients n (%)   Healthy controls n (%)
  ------------------------------ -------------------- ------------------------
  **Total no.**                  100 (100%)           100 (100%)
  **Gender**                                          
  Males                          62 (62%)             64 (64%)
  Females                        38 (38%)             36 (36%)
  **Age at diagnosis (Years)**                        
  ≤ 50                           61 (%)               66 (%)
  \> 50                          39 (%)               34 (%)
  Mean age (years)               49.82                47.89
  **HTN**                                             
  Yes                            63 (63%)             28 (28%)
  No                             37 (37%)             72 (72%)
  **Obesity**                                         
  Yes                            20 (20%)             5 (5%)
  No                             80 (80%)             95 (95%)
  **Smoking status**                                  
  Yes                            58 (58%)             30 (30%)
  No                             42 (42%)             70 (70%)
  **Alcoholism**                                      
  Yes                            49 (49%)             26 (26%)
  No                             51 (51%)             74 (74%)

The difference observed in genotype among cases and controls was found to be significant (p = 0.001) ([Table 2](#T2){ref-type="table"}). It was observed that high percentage of heterozygous GC 16 (16%) and mutant homozygous CC 8 (8%) genotype was found in patients compared to controls, heterozygous GC 8 (8%) and CC 0 (0%) while lower GG 76 (76%) genotype in patients compared to control homozygous GG 90 (90%) genotype. The higher allele frequency of C allele (0.16) was observed in T2D patients compared to control (0.04).

###### 

Genotype distribution and allele frequencies of *CRP* (+1056G/C) gene among T2D patients and controls

  Variables                GG n(%)   GC n(%)   CC n(%)   p value   Allele frequency   
  ------------------------ --------- --------- --------- --------- ------------------ ------
  **Patients (n = 100)**   76 (76)   16 (16)   8 (8)     0.001     0.84               0.16
  **Controls (n = 100)**   92 (92)   8 (8)     0 (0)     0.96      0.04               

Odds ratio with 95 % confidence intervals was calculated for each group to estimate the degree of association between the *CRP* genotype and risk of T2D in Indian patients depicted in [Table 3](#T3){ref-type="table"}. Compared to the GG genotype, the OR 2.72 (1.12-6.61) and 20.56 (1.16-362.1) for the heterozygous GC and homozygous CC genotypes were estimated, suggesting a possible dominant effect of *CRP* polymorphism on T2D risk.

###### 

Risk of T2D associated with *CRP* (+1056G/C) genotype

  Genotype   Healthy controls (n = 100)   T2D patients (n = 100)   OR (95% CI)
  ---------- ---------------------------- ------------------------ --------------------
  **GG**     92 (92%)                     76 (76%)                 **(ref)**
  GC         8 (8%)                       16 (16%)                 2.42 (0.98-5.96)
  CC         0 (0%)                       8 (8%)                   20.56 (1.16-362.1)
  GC+CC      8 (8%)                       24 (24%)                 3.63 (1.54-8.54)

The risk associated with Hypertension (HTN), Obesity, smoking and alcoholism was calculated in T2D patients and depicted in ([Table 4](#T4){ref-type="table"}). In HTN, compared to the GG genotype, the OR 1.52 (0.47-4.79), 4.82 (0.56-41.20) for the heterozygous GC and homozygous CC genotypes. In obesity, compared to the GG genotype, the OR 1.61 (0.44-5.80) and 2.90 (0.61-13.72) for the heterozygous GA and homozygous AA genotypes. Patients with smoking, alcoholism status compared to the GG genotype, the OR for GC 1.87 (0.59-5.92), 3.02 (0.95-9.56) and for CC 2.56 (0.48-13.51), 4.12 (0.78-21.79) respectively.

###### 

Risk of *CRP* genotype in T2D patients associated with different variables

  Genotype       HTN No (n = 37)           HTN Yes (63)               OR\* (95% CI)
  -------------- ------------------------- -------------------------- -------------------
  **GG**         **31**                    **45**                     **(ref)**
  GC             **5**                     **11**                     1.51 (0.47-4.79)
  CC             **1**                     **7**                      4.82 (0.56-41.20)
  **Genotype**   **Obesity No (n = 80)**   **Obesity Yes (n = 20)**   **OR\* (95% CI)**
  **GG**         **63**                    **13**                     **(ref)**
  GC             **12**                    **4**                      1.61 (0.44-5.80)
  CC             **5**                     **3**                      2.90 (0.61-13.72)
  **Genotype**   **Smoker No (n=42)**      **Smoker Yes (n=58)**      **OR\* (95% CI)**
  **GG**         35                        41                         **(ref)**
  GC             5                         11                         1.87 (0.59-5.92)
  CC             2                         6                          2.56 (0.48-13.51)
  **Genotype**   **Alcohol No (n=49)**     **Alcohol Yes (n=51)**     **OR\* (95% CI)**
  **GG**         32                        44                         **(ref)**
  GC             11                        5                          3.02 (0.95-9.56)
  CC             6                         2                          4.12 (0.78-21.79)

Other serum markers such as cholesterol, TG, LDL, VLDL, HDL, serum uric acid, bilirubin total, fasting blood glucose and postprandial glucose were compared between T2D patients, and healthy controls were shown in [table 6](#T6){ref-type="table"}. High lipid parameter such as TG, LDL, VLDL and were observed higher in T2D patients compared to controls and the differences was found to be significant (p \< 0.0001, p \< 0.0001, p \< 0.0001), however no significant difference was observed in cholesterol level among T2D cases and controls (p = 0.73). Serum uric acid and total bilirubin were observed to be high compared to healthy control group (p \< 0.0001, p \< 0.0001). High fasting and postprandial blood glucose were observed in T2D cases compared to healthy controls, and the difference was found to be significant (p \< 0.0001, p \< 0.0001).

###### 

Serum markers level of T2D patients and healthy controls

  Serum markers              T2D patients (Mean [+]{.ul} SD)   Healthy controls (Mean [+]{.ul} SD)   p-value
  -------------------------- --------------------------------- ------------------------------------- ----------
  Cholesterol                206.8 ± 43.02                     205.2 ± 19.05                         0.73
  TG                         183.3 ± 42.62                     139.5 ± 24.92                         \<0.0001
  LDL                        147.4 ± 28.77                     113.3 ± 14.10                         \<0.0001
  VLDL                       34.16 ± 5.62                      25.32 ± 4.81                          \<0.0001
  Serum uric acid            5.44 ± 1.85                       4.20 ± 0.74                           \<0.0001
  Bilirubin total            0.86 ± 0.44                       0.64 ± 0.20                           0.0003
  Fasting blood sugar        171.1 ± 39.55                     92.75 ± 10.88                         \<0.0001
  Postprandial blood sugar   257.7 ± 51.94                     126.7 ± 9.58                          \<0.0001

###### 

Effect of different risk factor positive on serum markers level among T2D patients and healthy controls

  HTN history yes              In T2D          Healthy control       p-value
  ---------------------------- --------------- --------------------- -------------
  Cholesterol                  208.3 ± 43.49   210.2 ± 17.95         0.82
  TG                           182.8 ± 43.10   138 ± 23.67           \< 0.0001
  LDL                          138.9 ± 27.19   118.4 ± 15.54         0.0003
  VLDL                         34.62 ± 5.74    26.32 ± 3.78          \< 0.0001
  Serum uric acid              5.51 ± 1.73     4.26 ± 0.59           \< 0.0001
  Bilirubin total              0.83 ± 0.43     0.67 ± 0.20           0.23
  Fasting blood sugar          174.8 ± 42.39   92.54 ± 11.66         \< 0.0001
  Postprandial blood sugar     256.2 ± 54.99   127.1 ± 1.60          \< 0.0001
  **Obesity history yes**      **In T2D**      **Healthy control**   **p-value**
  Cholesterol                  207.6 ± 45.59   208 ± 27.16           0.98
  TG                           194.4 ± 47.36   174.8 ± 49.06         0.42
  LDL                          140 ± 27.69     109.2 ± 12.66         0.02
  VLDL                         33.80 ± 5.55    23.60 ± 4.27          0.0009
  Serum uric acid              5.41 ± 1.51     4.02 ± 0.73           0.009
  Bilirubin total              0.68 ± 0.33     0.78 ± 0.16           0.16
  Fasting blood sugar          167.1 ± 31.61   93.0 ± 11.90          \< 0.0001
  Postprandial blood sugar     251.5 ± 56.60   128.8 ± 10.03         \< 0.0001
  **Alcoholism history yes**   **In T2D**      **Healthy control**   **p-value**
  Cholesterol                  210.7 ± 45.08   201.6 ± 18.35         0.33
  TG                           191.1 ± 44.13   136.0 ± 14.46         \< 0.0001
  LDL                          139.1 ± 28      117.2 ± 14.20         0.0004
  VLDL                         34.22 ± 5.46    24.81 ± 4.36          \< 0.0001
  Serum uric acid              5.75 ± 2.05     4.19 ± 0.87           0.0004
  Bilirubin total              0.87 ± 0.44     0.68 ± 0.20           0.08
  Fasting blood sugar          180.4 ± 46.93   93.42 [+]{.ul}11.73   \< 0.0001
  Postprandial blood sugar     262.6 ± 55.92   123.3 ± 9.04          \< 0.0001
  **Smoking history yes**      **In T2D**      **Healthy control**   **p-value**
  Cholesterol                  208.2 ± 42.54   203.5 ± 20.04         0.56
  TG                           185.8 ± 48.01   136.3 ± 24.74         \< 0.0001
  LDL                          139.4 ± 29.59   113.1 ± 12.85         \< 0.0001
  VLDL                         35.09 ± 6.06    25.0 ± 4.08           \< 0.0001
  Serum uric acid              5.44 ± 1.73     4.23 ± 0.92           0.0002
  Bilirubin total              0.82 ± 0.39     0.66 ± 0.21           0.03
  Fasting blood sugar          173.7 ± 42.02   92.0 ± 10.86          \< 0.0001
  Postprandial blood sugar     261.1 ± 57.51   128.3 ± 8.92          \< 0.0001

Patients and controls with different risk factor were analysed to see the effect on biochemical parameters, and it was observed that the patients and controls had hypertension history had a significant impact on biochemical parameters. T2D patients with HTN history had elevated level of TG, LDL, VLDL, Serum uric acid, bilirubin, fasting blood sugar and postprandial blood sugar compared to healthy control with HTN history. In the same way, others risk factors were found to affect most of the biochemical parameters and found to be significant.

Discussion {#sec1-4}
==========

Identification of the genetic determinants could facilitate the risk prediction of disease development and the implementation of individualised treatment for therapy. Up to now, genome-wide association studies (GWAS) for diabetes have identified more than 80 susceptibility loci, but only a small part of the heritability of diabetes can be explained by those findings \[[@ref12]\]. In the present study we observed a significant difference in the distribution of *CRP* genotype among T2D case and healthy controls, higher mutant allele distribution was observed among T2D cases compared to healthy controls. An independent association of mutant CC genotype and GC heterozygous genotype of *CRP* gene were found to be associated with increased risk of T2D.

It was observed that the CC and GC genotype in patients showed more than 20 and 2 fold increase risk of T2D compared to healthy controls. Patients with different status like hypertension (HTN), doing alcoholism showed more than 4 fold increased the risk of T2D with mutant CC genotypes of the *CRP* gene. However, obesity, smoking had mutant CC genotypes of *CRP* gene showed more than 2 fold higher risk of T2D. Hypertension, alcoholism, obesity and smoking behaviour are suggestive to a possible risk factor for developing T2D. It has been observed that several lipid parameters such as TG, LDL, and VLDL were found to be elevated in T2D cases compared to healthy controls.

Serum uric acid and total bilirubin were found to elevated in T2D compared to healthy controls as the basal values of *CRP* appear to be significantly heritable \[[@ref13]\]. D. Thalmaier *et al*. found that polymorphisms in the *CRP* gene and in genes controlling *CRP* expression influence *CRP* levels and *CRP* (+1059G/C) polymorphism involved in the same way \[[@ref14]\]. It has been observed that +1059 G/C (rs1800947) nucleotide polymorphism (SNP) in exon 2 of the *CRP* gene. +1059G/C is a synonymous polymorphism, which has been reported to affect the protein levels of *CRP* and contribute to the progression of CAD (coronary artery disease) and T2D \[[@ref15]\].

Hypertension is recognised globally as a major risk factor for CVD, stroke, diabetes, and renal diseases \[[@ref16]\]. Several studies have shown that most of the hypertensive patients have significant instability of serum lipid parameters in hypertensive patients \[[@ref17], [@ref18]\]. Smoking may be linked to impaired glucose and lipid metabolism, and a wealth of evidence indicates that insulin resistance, abnormal glucose and lipid metabolism \[[@ref19]\]. Parchwani DN *et al*. reported that glucose and altered lipid profile are directly found to be correlated with smoking and length of smoking years \[[@ref20]\], and Haggard also reported that smoking even a single could be the cause of increased blood sugar \[[@ref21]\].

It has been suggested moderate alcohol intake increases the risk of type 2 diabetes, especially in Japanese lean subjects \[[@ref22]\]. Considering facts that East Asian subjects with normal BMI level (\< 25kg/m^2^) can easily develop type 2 diabetes \[[@ref23]\], and large differences in the polymorphic distribution of alcohol-metabolizing enzymes have been reported between East Asian and Caucasian, the effects of alcohol intake on type 2 diabetes might vary according to ethnicity \[[@ref24]\].

The study concluded that *CRP* gene polymorphism was found to be associated with risk of Type 2 Diabetes and risk was linked with heterozygosity and mutant homozygosity.

Hypertension, Obesity, Smoking and alcoholism significantly altered biochemical parameters in Type 2 Diabetes patients. These interesting results of the study deserve further validation on a larger population.
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